Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

  • Cappuyns, Sarah
  • Piqué-Gili, Marta
  • Esteban-Fabró, Roger
  • Philips, Gino
  • Balaseviciute, Ugne
  • Pinyol, Roser|||0000-0002-0288-6314
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Vandecaveye, Vincent
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Montironi, Carla|||0000-0002-1453-2193
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Peix, Judit
  • Zeitlhoefler, Marcus
  • Mesropian, Agavni
  • Huguet Pradell, Júlia
  • Haber, Philipp K
  • Figueiredo, Igor
  • Ioannou, Giorgio
  • Gonzalez Kozlova, Edgar
  • D'Alessio, Antonio
  • Mohr, Raphael
  • Meyer, Tim
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Marquardt, Jens U
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Edeline, Julien
  • Finkelmeier, Fabian
  • Trojan, Jorg
  • Galle, Peter R
  • Foerster, Friedrich
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Montal, Robert
  • Gnjatic, Sacha
  • Pinato, David James|||0000-0002-3529-0103
  • Heikenwälder, Mathias
  • Verslype, Chris
  • Van Cutsem, Eric|||0000-0002-6372-1230
  • Lambrechts, Diether
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Dekervel, Jeroen
  • Llovet, Josep M.|||0000-0003-0547-2667
The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit vs. resistance to atezo+bev. We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of patients with advanced HCC treated with atezo+bev (n = 317) vs. atezolizumab (n = 47) or sorafenib (n = 58) as comparators. We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterised by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune-rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs. sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define " Immune-competent " and " Angiogenesis-driven " molecular subgroups, each associated with a significantly longer OS with atezo+bev vs. sorafenib (p of interaction = 0.027), and a " Resistant" subset. Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC (" Immune-competent" and " Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance. Atezolizumab + bevacizumab (atezo+bev) is standard of care in advanced hepatocellular carcinoma (HCC), yet molecular determinants of clinical benefit to the combination remain unclear. This study harnesses the power of single-cell RNA sequencing, deriving gene expression signatures representing 21 cell subtypes in the advanced HCC microenvironment. By applying these signatures to RNA-sequencing samples, we reveal two distinct response patterns to atezo+bev and define molecular subgroups of patients (" Immune-competent" and " Angiogenesis-driven" vs. "Resistant") with differential clinical outcomes upon treatment with atezo+bev, pointing towards the role of immunosuppressive myeloid cell types and Notch pathway activation in primary resistance to atezo+bev. These results may help refine treatment strategies and improve outcomes for patients with advanced HCC, while also guiding future research aimed at overcoming resistance mechanisms.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The multiomics blueprint of the individual with the most extreme lifespan

  • Santos-Pujol, Eloy
  • Vasallo, Claudia
  • Gabaldón Estevan, Juan Antonio, 1973-
  • Brigos-Barril, Eva
  • Moldes, Mauricio
  • Muntané, Gerard
  • Laayouni, Hafid, 1968-
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Esteller, Manel
Extreme human lifespan, exemplified by supercentenarians, presents a paradox in understanding aging: despite advanced age, they maintain relatively good health. To investigate this duality, we have performed a high-throughput multiomics study of the world's oldest living person, interrogating her genome, transcriptome, metabolome, proteome, microbiome, and epigenome, comparing the results with larger matched cohorts. The emerging picture highlights different pathways attributed to each process: the record-breaking advanced age is manifested by telomere attrition, abnormal B cell population, and clonal hematopoiesis, whereas absence of typical age-associated diseases is associated with rare European-population genetic variants, low inflammation levels, a rejuvenated bacteriome, and a younger epigenome. These findings provide a fresh look at human aging biology, suggesting biomarkers for healthy aging, and potential strategies to increase life expectancy. The extrapolation of our results to the general population will require larger cohorts and longitudinal prospective studies to design potential anti-aging interventions., We thank Yoana Veselinova for the drawing of the graphical abstract. Research in the M.E. group is funded by the CERCA Programme/Generalitat de Catalunya (MCIN/AEI/10.13039/501100011033/); the European Regional Development Fund, "A way to make Europe" ERDF (Project PID2021-125282OB-I00 and PID2024-159192OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494); European Union under THRIVE grant agreement no. 101136622; "La Caixa" Research Foundation; and the Cellex Foundation (CEL007). E.S.-P. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPI contract no. PRE2022-105015. G.F. is a recipient of Ayuda Investigador AECC 2023 (INVES234765FERR), Fundación Científica AECC. C.Q.-D. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPU contract no. FPU22/01655. E.M.'s work in this publication was supported by the Ramón y Cajal fellowship RYC2021-032359-I, funded by the Spanish Ministry of Science and the Catalan Government. Agency for Management of University and Research Grants (AGAUR, 2021 SGR 01586). Research in the A.N. group is supported by the I+D+i project PID2021-127792NB-I00, funded by MCIN/AEI/10.13039/501100011033 (FEDER Una manera de hacer Europa), and "Unidad de Excelencia María de Maeztu", funded by the AEI (CEX2018-000792-M) and Departament de Recerca i Universitats de la Generalitat de Catalunya (GRC 2021 SGR 0467). Research in the R.C.-T. group is funded by the Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01366). Research in the S.M. group was supported by the Instituto de Salud Carlos III (PI20/00328) and the M. C. Andreu Memorial Fund. J. R.-B. was supported by a doctoral grant from the Universitat Oberta de Catalunya. Research in the M.A.B. laboratory is funded by the European Union, project ERC-AvG Shelterins (GA 882385), Horizon 2020 Programme. The mass spectrometry work was supported by the John and Lucille Van Geest Foundation and the National Institute for Health and Care Research Leicester Biomedical Research Centre. M.E. is an ICREA Research Professor. Special thanks are given to personnel taking care of M116 and to all of the biobank technicians involved in and contributing to keeping samples and procedures for the current research, with special mention to Gerard Pardo Albiñana.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A technical comparison of spatial transcriptomics platforms across six cancer types

  • Cervilla, Sergi
  • Grases, Daniela
  • Pérez, Elena
  • Real, Francisco X.
  • Musulen, Eva
  • Aprea, Julieta
  • Esteller, Manel
  • Porta-Pardo, Eduard
Background: Spatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology. Results: Here, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. Conclusions: Collectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors., This work was supported by Nanostring and Longwood Laboratories (who funded the CosMx experiments), 10x Genomics and Bonsai Labs (who funded the Xenium experiments), and Asociación Española Contra el Cáncer (who funded the VISIUM experiments, LABAE20038PORT). S.C is supported by AECC (LABAE20038PORT). E.P-P is supported by the Spanish Ministry of Science (RYC2019-026415-I), a Fundación FERO fellowship (BFERO2022.6), grant PID2024-159258OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01309). S.C. is supported by the FI-STEP predoctoral grants program of the Department of Research and Universities of the Government of Catalonia (Generalitat de Catalunya), and co-financing by the European Social Fund Plus (2025 STEP 00466) ME is supported by MCIN/AEI/10.13039/501100011033 /and the European Regional Development Fund, ‘A way to make Europe’ ERDF (project PID2021-125282OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494), European Union under THRIVE Grant Agreement Nr. 101136622 and Fundación Científica de la Asociación Contra el Cáncer (ASPIRE project, RETOS245779LLOV).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ribosomal S6 kinase 1 regulates inflammaging via the senescence secretome

  • Gallage, Suchira
  • Irvine, Elaine E.
  • Barragán Ávila, José Efrén
  • Reen, Virinder
  • Pedroni, Silvia M. A.
  • Duran, Imanol
  • Ranvir, Vikas
  • Khadayate, Sanjay
  • Pombo, Joaquim
  • Brookes, Sharon
  • Heide, Danijela
  • Dharmalingham, Gopuraja
  • Choudhury, Agharul I.
  • Singh, Indrabahadur
  • Herranz, Nicolás
  • Vernia, Santiago
  • Heikenwalder, Mathias
  • Gil, Jesús
  • Withers, Dominic J.
Inhibition of S6 kinase 1 (S6K1) extends lifespan and improves healthspan in mice, but the underlying mechanisms are unclear. Cellular senescence is a stable growth arrest accompanied by an inflammatory senescence-associated secretory phenotype (SASP). Cellular senescence and SASP-mediated chronic inflammation contribute to age-related pathology, but the specific role of S6K1 has not been determined. Here we show that S6K1 deletion does not reduce senescence but ameliorates inflammation in aged mouse livers. Using human and mouse models of senescence, we demonstrate that reduced inflammation is a liver-intrinsic effect associated with S6K deletion. Specifically, we show that S6K1 deletion results in reduced IRF3 activation; impaired production of cytokines, such as IL1β; and reduced immune infiltration. Using either liver-specific or myeloid-specific S6K knockout mice, we also demonstrate that reduced immune infiltration and clearance of senescent cells is a hepatocyte-intrinsic phenomenon. Overall, deletion of S6K reduces inflammation in the liver, suggesting that suppression of the inflammatory SASP by loss of S6K could underlie the beneficial effects of inhibiting this pathway on healthspan and lifespan., Core support from the Medical Research Council (MRC) (MC_U120085810) and Cancer Research UK (CRUK) (C15075/A28647) funded this research in the Gil laboratory. M.H. was supported by a European Research Council Consolidator grant (HepatoMetaboPath); the European Commission (Horizon EuropeMission Cancer, THRIVE, ref. 101136622); SFB/TR 209 (project ID: 314905040); SFB 1479 (project ID: 441891347); SFB 1479; the Rainer Hoenig Foundation; Research Foundation Flanders under grant 30826052 (EOS Convention MODEL-IDI); and seed funding from HI-TRON. This work was also supported by MRC grant MC-A654-5QB40 and Wellcome Trust Grant 098565/Z/12/Z in the Withers laboratory., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer

  • Wagner, Verena
  • Bousset, Laura
  • Ascensao-Ferreira, Mariana
  • Sun, Bin
  • Barragán Ávila, José Efrén
  • Kaizeler, Alexandre
  • Martins-Silva, Rita
  • Rahbari, Mohammad
  • Fernández-Vaquero, Mirian
  • Haston, Scott
  • Tinti, Michele
  • Pombo, Joaquim
  • Khadayate, Sanjay
  • Roth, Susanne
  • Schurch, Christian M.
  • Martínez-Barbera, Juan Pedro
  • Bahat, Anat
  • Wee, Keng Boon
  • Morton, Jennifer P.
  • Malek, Nisar
  • Innes, Andrew J.
  • Vernia, Santiago
  • Barbosa-Morais, Nuno L.
  • Gallage, Suchira
  • Heikenwalder, Mathias
  • Gil, Jesús
RAS family proteins, including HRAS, NRAS, and KRAS, are frequently mutated in cancer. Although there has been recent success in designing inhibitors that target oncogenic RAS, they elicit resistance and treating RAS-driven cancer remains difficult. Here, employing a proteomic analysis, we find that multiple spliceosome components are upregulated in the nuclei of cells undergoing RAS-induced senescence. This upregulation depends on RAS signalling and occurs in both senescent preneoplastic and fully transformed cancer cells. Spliceosome components are also highly expressed in preneoplastic and cancerous lesions in human and murine lung, liver, colorectal, and pancreatic cancers. Using siRNA screens, we identify six spliceosome components, including SF3B1 and RBM39, that are essential in cells expressing oncogenic RAS. We find that SF3B1 is required in these cells for maintaining splicing fidelity. By combining transcriptome and splicing analyses with functional screens, we identify the RNA Pol II-associated factor SPT5 as a key mediator of the SF3B1 effects. Importantly, using mouse models of liver cancer, we show that RBM39 and SF3B1 inhibitors are effective in targeting both preneoplastic lesions and aggressive tumours expressing oncogenic RAS. In summary, our study highlights the spliceosome as a promising target for RAS-driven cancers capable of inhibiting both cancer initiation and progression., We acknowledge the support of the Biobank of the European Pancreas Center (EPC), Heidelberg. S.V. was supported by the Medical Research Council (MRC, MC_UP_1102/18). M.T. was supported by the Wellcome Trust (101842/Z/13/Z). J.P.M.-B. was funded by Cancer Research UK (C54322/A27727), the Brain Tumour Charity (EVEREST (GN-000382) and GN-000522), CHILDREN with CANCER UK(CwCUK15-190) and National Institutes of Health Research Biomedical Research Center at the Great Ormond Street Hospital for Children NHS Foundation Trust, and the University College London. J.P.M. was supported by CRUK (A31287, A29996, A25233). K.B.W. wasfundedbytheA*STARIndustryAlignment Fund, Grant/Award Number: H20H6a0027. M.A.-F., A.K., and R.M.-S. were funded by Fundação para a Ciência e a Tecnologia (FCT, PhD studentships PD/BD/128283/2017, UI/BD/153363/2022, and UI/BD/ 153368/2022, respectively). N.L.B.-M. was funded by FCT (CEECIND/ 00436/2018)andEMBO(InstallationGrant3057).S.G.wassupportedby a Max-Eder Junior Research Group Program of the Deutsche Krebshilfe (German Cancer Aid- Project ID: 70116308). M.H. was supported by a European Research Council (ERC) Consolidator grant (HepatoMetaboPath), the ERC POC (Faith), the European Commission (Horizon EuropeMission Cancer, THRIVE, Ref. 101136622), the Helmholtz Future topic Inflammation and Immunology, Zukunftssthema ‘Immunology and Inflammation’ (ZT-0027), SFB/TR 412 (Project ID: 535081457), SFB/ TR 209 (Project ID: 314905040), SFB 1479 (Project ID: 441891347), SFBTR 179 (Project ID: 272983813), the Rainer Hoenig Stiftung, Research Foundation Flanders (FWO) under grant 30826052 (EOS Convention MODEL-IDI) and a seed funding from HI-TRON. Research in the C.M.S. laboratory was funded by the Department of Pathology, University Hospital Tübingen. V.W. wasfundedbytheGermanCancerAidMildredScheel Postdoctoral Fellowship Program. Core support from MRC (MC_U120085810) and CRUK (C15075/A28647; DRCPGM-Jun25/ 100003) funded this research in J. Gil’slaboratory., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A technical comparison of spatial transcriptomics platforms across six cancer types

  • Cervilla, Sergi
  • Grases, Daniela
  • Pérez, Elena
  • Real, Francisco X.
  • Musulen, Eva
  • Aprea, Julieta
  • Esteller, Manel
  • Porta-Pardo, Eduard
Background: Spatial transcriptomics (ST) technologies are reshaping our understanding of tissue organization and cellular context in health and disease. However, technical benchmarking across platforms remains limited, particularly in formalin-fixed, paraffin-embedded (FFPE) clinical samples, which represent the most common tissue format in oncology. Results: Here, we systematically benchmark five commercial ST platforms (Visium v1, Visium v2/CytAssist, Visium HD, Xenium, and CosMx) using matched FFPE human tumor sections from six cancer types. Uniquely, our study includes both sequencing-based and imaging-based platforms profiled on the same samples, enabling direct technical comparisons across spatial capture modalities. We evaluate platform performance across multiple dimensions, including transcript and UMI detection, gene-histology concordance, cell type recovery, and integration with a targeted protein panel (Visium v2, 30 proteins), enabling spatial multi-omics. We also quantify the impact of sampling strategies and area coverage on cell type estimation, revealing trade-offs in spatial resolution versus tissue context. Notably, we present the first same-sample comparison of Xenium Multi-Tissue (377 genes) and Xenium Prime (5,000 genes), highlighting key differences in transcript recovery and spatial signal despite shared chemistry and imaging infrastructure. Finally, we integrate Visium targeted protein data with matched RNA profiles, uncovering widespread RNA-protein decoupling and spatial heterogeneity in concordance. Conclusions: Collectively, this work provides a harmonized dataset and technical reference for the spatial transcriptomics community, offering insight into the relative strengths, limitations, and design considerations associated with high-throughput spatial profiling of FFPE tumors., This work was supported by Nanostring and Longwood Laboratories (who funded the CosMx experiments), 10x Genomics and Bonsai Labs (who funded the Xenium experiments), and Asociación Española Contra el Cáncer (who funded the VISIUM experiments, LABAE20038PORT). S.C is supported by AECC (LABAE20038PORT). E.P-P is supported by the Spanish Ministry of Science (RYC2019-026415-I), a Fundación FERO fellowship (BFERO2022.6), grant PID2024-159258OB-I00 funded by MICIU/AEI/ 10.13039/501100011033 and Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01309). S.C. is supported by the FI-STEP predoctoral grants program of the Department of Research and Universities of the Government of Catalonia (Generalitat de Catalunya), and co-financing by the European Social Fund Plus (2025 STEP 00466) ME is supported by MCIN/AEI/10.13039/501100011033 /and the European Regional Development Fund, ‘A way to make Europe’ ERDF (project PID2021-125282OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494), European Union under THRIVE Grant Agreement Nr. 101136622 and Fundación Científica de la Asociación Contra el Cáncer (ASPIRE project, RETOS245779LLOV).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The multiomics blueprint of the individual with the most extreme lifespan

  • Santos-Pujol, Eloy
  • Vasallo, Claudia
  • Gabaldón Estevan, Juan Antonio, 1973-
  • Brigos-Barril, Eva
  • Moldes, Mauricio
  • Muntané, Gerard
  • Laayouni, Hafid, 1968-
  • Navarro i Cuartiellas, Arcadi, 1969-
  • Esteller, Manel
Extreme human lifespan, exemplified by supercentenarians, presents a paradox in understanding aging: despite advanced age, they maintain relatively good health. To investigate this duality, we have performed a high-throughput multiomics study of the world's oldest living person, interrogating her genome, transcriptome, metabolome, proteome, microbiome, and epigenome, comparing the results with larger matched cohorts. The emerging picture highlights different pathways attributed to each process: the record-breaking advanced age is manifested by telomere attrition, abnormal B cell population, and clonal hematopoiesis, whereas absence of typical age-associated diseases is associated with rare European-population genetic variants, low inflammation levels, a rejuvenated bacteriome, and a younger epigenome. These findings provide a fresh look at human aging biology, suggesting biomarkers for healthy aging, and potential strategies to increase life expectancy. The extrapolation of our results to the general population will require larger cohorts and longitudinal prospective studies to design potential anti-aging interventions., We thank Yoana Veselinova for the drawing of the graphical abstract. Research in the M.E. group is funded by the CERCA Programme/Generalitat de Catalunya (MCIN/AEI/10.13039/501100011033/); the European Regional Development Fund, "A way to make Europe" ERDF (Project PID2021-125282OB-I00 and PID2024-159192OB-I00); Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01494); European Union under THRIVE grant agreement no. 101136622; "La Caixa" Research Foundation; and the Cellex Foundation (CEL007). E.S.-P. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPI contract no. PRE2022-105015. G.F. is a recipient of Ayuda Investigador AECC 2023 (INVES234765FERR), Fundación Científica AECC. C.Q.-D. is a fellow of the Spanish Ministry of Science, Innovation and Universities, under FPU contract no. FPU22/01655. E.M.'s work in this publication was supported by the Ramón y Cajal fellowship RYC2021-032359-I, funded by the Spanish Ministry of Science and the Catalan Government. Agency for Management of University and Research Grants (AGAUR, 2021 SGR 01586). Research in the A.N. group is supported by the I+D+i project PID2021-127792NB-I00, funded by MCIN/AEI/10.13039/501100011033 (FEDER Una manera de hacer Europa), and "Unidad de Excelencia María de Maeztu", funded by the AEI (CEX2018-000792-M) and Departament de Recerca i Universitats de la Generalitat de Catalunya (GRC 2021 SGR 0467). Research in the R.C.-T. group is funded by the Departament de Recerca i Universitats/Generalitat de Catalunya (2021 SGR 01366). Research in the S.M. group was supported by the Instituto de Salud Carlos III (PI20/00328) and the M. C. Andreu Memorial Fund. J. R.-B. was supported by a doctoral grant from the Universitat Oberta de Catalunya. Research in the M.A.B. laboratory is funded by the European Union, project ERC-AvG Shelterins (GA 882385), Horizon 2020 Programme. The mass spectrometry work was supported by the John and Lucille Van Geest Foundation and the National Institute for Health and Care Research Leicester Biomedical Research Centre. M.E. is an ICREA Research Professor. Special thanks are given to personnel taking care of M116 and to all of the biobank technicians involved in and contributing to keeping samples and procedures for the current research, with special mention to Gerard Pardo Albiñana.